NA | ELOXATIN [Aventis Pharma Ltd.] | BioPortfolio

12:16 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

NDC 12516-0592-4

ELOXATIN® (oxaliplatin injection)200 mg/40mL vial


QUANTITY: 240 vials

LOT: **********


EXP: **********

PROCESS ORDER No: **********

WEIGHT: 20.6kg

Caution: For manufacturing, processing or repacking.

Rx only.

Store at 25°C (77°F); excursions permitted to 15 - 30°C (59 - 86°F).

Do not freeze and protect from light

Manufactured by:Aventis Pharma Ltd. Rainham Rd South, Dagenham, Essex, RM10 7XS, UK

Made in UK



Aventis Pharma Ltd.

Active Ingredients


Drugs and Medications [0 Results]


Clinical Trials [21 Associated Clinical Trials listed on BioPortfolio]

Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma

Primary objective: To determine the Tumor Response Rate of patients with hepatocellular carcinoma treated with the combination chemotherapy of Eloxatin+5-FU/LV Secondary objective:...

A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC

This is a Phase II, open-label, non-randomized study in patients with advanced non-squamous NSCLC. Each cycle will be 21 days. Patients will be evaluated every 2 cycles (~6 weeks) for ...

Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma

In patients with pleural or peritoneal mesothelioma, what is the response rate to combined Oxaliplatin (ELOXATIN®) and Gemcitabine chemotherapy?

XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer

XELOX (Capecitabine and Oxaliplatin) is an effective and convenient regimen for patients with metastatic colorectal cancer. Chronomodulated therapy may reduce toxicity. Patients will be ra...

Clinical Studies of Gemcitabine-Oxaliplatin

These are Phase 2 single-arm studies of gemcitabine in combination with oxaliplatin in refractory or relapsing pediatric solid tumors.

PubMed Articles [0 Results]


Quick Search


Relevant Topic

Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...

Drugs and Medication Quicklinks

Searches Linking to this Drug Record